Firm’s CER-001 program is currently in IND-enabling studies.

Cerenis Therapeutics has received a €2.5 million, or approximately $3.2 million, investment to finance its pipeline of HDL-related products for the treatment of cardiovascular and metabolic diseases.

The financing will support continued development of the company’s CER-001 program (recombinant HDL), which is currently in preclinical studies.

The funds were granted by OSEO, a French public holding company that provides financial support to promising French companies.

In 2008, the company initiated preclinical studies to enable an IND application for this product candidate. “This new source of funding will support our efforts to advance Cerenis HDL through the IND process and onto clinical development,” says Jean-Louis Dasseux, Ph.D., president and CEO of Cerenis. “We are grateful to OSEO for its generous support of our efforts to bring this promising product candidate to market.”ADNFCR-2184-ID-19019095-ADNFCR

Previous articleSyngenta Agrees to Eight-Year Collaboration with Chinese Academy
Next articleRearrangements During SRP-SR Binding and Activation Controls Protein Targeting